The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Starinskiĭ V.V.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

Sergeeva N.S.

Russian University of Peoples' Friendship

Marshutina N.V.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

Korneeva I.A.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Problems in the early diagnosis and screening of ovarian cancer: Reality and prospects

Authors:

Starinskiĭ V.V., Sergeeva N.S., Marshutina N.V., Korneeva I.A.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2013;2(1): 56‑62

Read: 1786 times

Download PDF (RU)
Contact the author
Table of contents

PROBLEMS IN THE EARLY DIAGNOSIS AND SCREENING OF OVARIAN CANCER: REALITY AND PROSPECTS
PROBLEMS IN THE EARLY DIAGNOSIS AND SCREENING OF OVARIAN CANCER: REALITY AND PROSPECTS

To cite this article:

Starinskiĭ VV, Sergeeva NS, Marshutina NV, Korneeva IA. Problems in the early diagnosis and screening of ovarian cancer: Reality and prospects. P.A. Herzen Journal of Oncology. 2013;2(1):56‑62. (In Russ.)

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
A mega­polis school children medi­cal check-up: orga­nizational approaches problems and their solu­tions. Russian Journal of Preventive Medi­cine. 2025;(3):20-25
Prevalence of cere­brovascular diseases risk factors acco­rding to the cohort survey data in Bishkek, Kyrgyz Repu­blic. Russian Journal of Preventive Medi­cine. 2025;(3):34-39
Diagnosis and treatment of ovarian cancer in pregnancy. Russian Bulletin of Obstetrician-Gynecologist. 2025;(3):27-33
Prevalence of postpartum depression in the Russian Fede­ration: a systematic review and meta-analysis. Medi­cal Technologies. Asse­ssment and Choice. 2025;(2):74-87
Guidelines for asse­ssing the quality of mammographic images. Russian Journal of Preventive Medi­cine. 2025;(6):21-32
Resu­lts of a 5-year project for the early diagnosis of multiple scle­rosis in first-line blood rela­tives (RADIRS program). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):28-33
Arti­ficial inte­lligence in reproductive medi­cine and surgery. Russian Journal of Human Reproduction. 2025;(4):10-25
The impo­rtance of screening preventive examination at the outpatient stage. Russian Journal of Preventive Medi­cine. 2025;(10):99-102
Modern stra­tegies for early diagnosis of cardiotoxicity caused by chemotherapy. Russian Journal of Preventive Medi­cine. 2025;(11):113-120
Orga­nization of moni­toring of carriers of pathogenic germline variants asso­ciated with here­ditary tumor syndromes based on a personalized approach. Medi­cal Technologies. Asse­ssment and Choice. 2025;(4):84-90
Abstract:

The review deals with screenings for the early/active detection of ovarian cancer (OC). It analyzes whether it is expedient to screen in accordance with the criteria laid down by WHO experts and provides rationales for the use of serological tumor markers for the active detection of cancer, as well as factors that may distort the valid assessment of screening tests and programs. The review systematizes the results of a number of multicenter controlled randomized programs to identify OC using the serological markers, chiefly CA 125, in combination with transvaginal ultrasonography and discusses the prospects and limitations of OC.

Keywords:

ovarian cancer
early diagnosis
screening

Authors:

Starinskiĭ V.V.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

Sergeeva N.S.

Russian University of Peoples' Friendship

Marshutina N.V.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

Korneeva I.A.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Close metadata

References:

  1. Chissov V.I., Starinskii V.V., Gnatyuk A.P. Aleksandrova L.M., Vazhenin A.V., Domozhirova A.S. Natsional'naya onkologicheskaya programma okazaniya spetsializirovannoi meditsinskoi pomoshchi onkologicheskim bol'nym i etapy ee razvitiya. Rossiiskii onkologicheskii zhurnal. 2009; 6: 43-5.
  2. Natsional'nye programmy bor'by protiv raka. Zheneva: VOZ; 1955. 76 s.
  3. Faten-Moghadam A., Stieber P. Sensible use of tumor markers. Basel: Switzerland: Springer Verlag; 1993; 70 p.
  4. Diamindis Fleisher M., Dnistrian A.M., Sturgeon M. Practice guidelines and recommendations for use of tumor markers in the clinic. Laboratory medicine practice guidelines. 2002; 15: 1-56.
  5. Sergeeva N.S., Marshutina N.V. Serologicheskie opukholeassotsiirovannye markery. V kn.: Chissov V.I., Davydov M.I., red. Onkologiya. Natsional'noe rukovodstvo. M.: GEOTAR-Media; 2008; 8-26.
  6. Bast R.C. Jr., Xu F.J., Yu Y.H., Barnhill S., Zhang Z., Mills G.B. CA 125: the past and the future. Int. J. Biol. Markers. 1998; 13 (4): 179-87.
  7. Helzlsouer K.J., Bush T.L., Alberg A.J., Bass K.M., Zacer H., Comstock G.W. Prospective study of serum CA 125 levels as markers of ovarian cancer. J. A. M. A. 1993; 269: 1123-6.
  8. Jellum E., Andersen A., Lund-Larsen P., Theodorsen L., Orjasaeter H. Experiences of the Janus serum bank in Norway. Environ. Health Perspect. 1995; 103 (Suppl. 3): 85-8.
  9. Menon U., Scates S., Macdonald N. Risk of ovarian cancer algorithm (ROCA) for the early detection of ovarian cancer. Tumor Biol. 2000; 21 (1): 15.
  10. European Association of Urology. Guidelines on prostate cancer. A. Heidenreich, M. Bolla S., Joniau, M.D. Mason, V. Matveev, N. Mottet, H.-P. Schmid et al. 2010: 14-6.
  11. Chissov V.I., Starinskii V.V., Petrova G.V., red. Zlokachestvennye novoobrazovaniya v Rossii v 2009 godu (zabolevaemost' i smertnost'). M.; 2011. 259 s.
  12. Novikova E.G., Ronina E.A., Korneeva I.A. Zlokachestvennye opukholi yaichnikov. V kn.: Chissov V.I., Davydov M.I., red. Onkologiya. Natsional'noe rukovodstvo. M.: GEOTAR-Media; 2008; 812-9.
  13. Kharitonova T.V. Sovremennye standarty lecheniya raka yaichnikov. Sovremennaya onkologiya. 2003; 5 (2): 44-7.
  14. Chissov V.I., Dar'yalova S.L., red. Klinicheskie rekomendatsii. Onkologiya. M.: GEOTAR-Media; 2006. 720 s.
  15. Clarke-Pearson D.L. Screening for ovarian cancer. N. Engl. J. Med. 2009; 361: 170-7.
  16. Moore R., Brown A., Miller M., Badgwell D., Lu Z., Allard W. et al. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol. Oncol. 2008; 110: 196-201.
  17. Moore R.G., Brown A.K., Miller M.C., Skates S., Allard W.J., Verch T. et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol. Oncol. 2008; 108 (2): 402-8.
  18. Urmancheeva A.F., Meshkova I.E. Voprosy epidemiologii i diagnostiki raka yaichnikov. Prakticheskaya onkologiya: Rak yaichnikov. 2000; 4 (12): 7-13.
  19. Rosenthal A.N., Jacobs I.J. The role of CA 125 in screening for ovarian cancer. Int. J. Biol. Marcers. 1998; 13 (4): 216-20.
  20. Jeyarajah A.R., Ind T.E., MacDonald N., Skates S., Oram D.H., Jacobs I.J. Increased mortality in postmenopausal women with serum CA 125 elevation. Gynecol. Oncol. 1999; 73 (2): 242-6.
  21. Masahashi T., Matsuzawa K., Ohsawa M., Narita O., Asai T., Ishihara M. Serum CA 125 levels in patients with endometriosis: changes of CA 125 levels during menstruation. Obstet. Gynecol. 1988; 72 (3): 328.
  22. Holbert T.R. Screening transvaginal ultrasonography of postmenopausal women in a private office setting. Am. J. Obstet. Gynecol. 1994; 170 (6): 1699-703.
  23. Taranov A.G. Antigen uglevodnyi rakovyi SA 125. Diagnosticheskie test-sistemy (radioimunnyi i immunofermentnyi metody diagnostiki). M.: Izdatel' Makeev; 2002: 169-71.
  24. Tumor markers in gynaecological cancers - EGTM recommendations European Group on Tumor Markers. Anticancer Res. 1999; 19 (4a): 2807-10.
  25. ACOG Committee Opinion Number 280: The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer. Obstet. Gynecol. 2002; 100: 1413.
  26. Sergeeva N.S., Akhmedova S.A., Storozhenko I.V., Mishunina M.P., Marshutina N.V., Novikova E.G. Sravnitel'naya otsenka znacheniya opukholevykh markerov SA 125 i SA 19-9 v monitoringe raka yaichnikov. Rossiiskii onkologicheskii zhurnal. 2001; 2: 22-4.
  27. Bell R., Petticrew M., Luengo S., Sheldon T.A. Screening for ovarian cancer: a systematic review. Health Technol. Assess. (Review). 1998; 2 (2): 1-84.
  28. Skates S.J., Xu F.J., Yu Y.H., Sjövall K., Einhorn N., Chang Y. et al. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer. 1995; 76 (1): 2004-10.
  29. Menon U., Skates S.J., Lewis S., Rosenthal A.N., Rufford B., Sibley K. et al. Prospective study using the risk of ovariancancer algorithm to screen for ovarian cancer. J. Clin. Oncol. 2005; 23: 7919-26.
  30. Skates S.J., Menon U., MacDonald N., Rosenthal A.N., Oram D.H., Knapp R.C., Jacobs I.J. Calculation of the risk of ovarian cancer from serial CA 125 values for preclinical detection in postmenopausal women. Clin. Oncol. 2003; 21: 206s-10.
  31. Jacobs I.J., Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol. Cell Proteomics. 2004; 3 (4): 355-66.
  32. Menon U., Gentry-Maharaj A., Hallett R., Ryan A., Burnell M., Sharma A. et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009; 10: 327-40.
  33. Kirchhoff C., Habben I., Ivell R., Krull N. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular protease inhibitors. Biol. Reprod. 1991; 45: 350-7.
  34. Kirchhoff C. Molecular characterization of epididymal proteins. Rev. Reprod. 1998; 3: 86-95.
  35. Bouchard D., Morisset D., Bourbonnais Y., Tremblay G.M. Proteins with whey- acidic-protein motifs and cancer. Lancet Oncol. 2006; 7: 167-74.
  36. Hellström I., Raycraft J., Hayden-Ledbetter M., Ledbetter J.A., Schummer M., McIntosh M. et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003; 63: 3695-700.
  37. Drapkin R., von Horsten H.H., Lin Y., Mok S.C., Crum C.P., Welch W.R., Hecht J.L. Human epididymis protein 4(HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005; 65: 2162-9.
  38. Galgano M.T., Hampton G.M., Frierson H.F. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod. Pathol. 2006; 19: 847-53.
  39. Hough C.D., Sherman-Baust C.A., Pizer E.S., Montz F.J., Im D.D., Rosenshein N.B. et al. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res. 2000; 60: 6281-7.
  40. Li J., Dowdy S., Tipton T., Podratz K., Lu W.G., Xie X., Jiang S.W. HE4 as a biomarker for ovarian and endometrial cancer management. Expert Rev. Mol. Diagn. 2009; 9 (6): 555-66.
  41. Moore R.G., McMeekin D.S., Brown A.K., DiSilvestro P., Miller M.C., Allard W.J. et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol. Oncol. 2009; 112: 40-6.
  42. Havrilesky L.J., Whitehead C.M., Rubatt J.M., Cheek R.L., Groelke J., He Q. et al. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol. Oncol. 2008; 110 (3): 374-82.
  43. Vorob'ev A.V., Protasova A.E. Obshchie voprosy skrininga. Prakticheskaya onkologiya. Problemy skrininga v onkologii. 2010; 11 (2): 53-9.
  44. Shapiro S. Periodic screening for breast cancer: the HIP Randomized Controlled Trial Health Insurance Plan. J. Natl. Cancer Inst. Monogr. 1997; 22: 27-30.
  45. Mandel J.S., Church T.R., Bond J.H. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J. Natl. Cancer Inst. 1999; 91: 434-7.
  46. Novik V.I. Epidemiologiya raka sheiki matki, faktory riska, skrining. Prakticheskaya onkologiya: Rak sheiki matki. 2002; 3 (3): 156-65.
  47. Sergeeva N.S., Dubovetskaya O.B., Marshutina N.V., Novikova E.G., Ashrafyan L.A., Mishunina M.P. Opukholeassotsiirovannyi marker SSS na etapakh lecheniya i v monitoringe bol'nykh rakom sheiki matki. Rossiiskii onkologicheskii zhurnal. 2004; 4: 12-4.
  48. Sergeeva N.S., Rodina I.A., Rusakov I.G., Ul'yanov R.V., Marshutina N.V., Kirsanova V.A. Issledovanie UBC-antigena kak vozmozhnogo urinologicheskogo markera raka mochevogo puzyrya. Rossiiskii onkologicheskii zhurnal. 2004; 1: 30-3.
  49. Einhorn N., Sjovall K., Knapp R.C., Hall P., Scully R.E., Bast R.C. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. J. Obstet. Gynecol. 1992; 80: 14-8.
  50. Jacobs I., Davies A.P., Bridges J., Menon U., Rosenthal A.N., Davies A.P. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. Br. Med. J. 1993; 306 (6884): 1030-4.
  51. Grover S., Quinn M.A., Weideman P., Koh H., Robinson H.P., Rome R. Screening for ovarian cancer using serum CA 125 and vaginal examination: report on 2550 females. Int. J. Gynecol Cancer. 1995; 5: 291-5.
  52. Adonakis G.L., Paraskevaidis E., Tsiga S., Seferiadis K., Lolis D.E. A combined approach for the early detection of ovarian cancer in asymptomatic women. Eur. J. Obstet. Gynecol. Reprod. Biol. 1996; 65 (2): 221-5.
  53. Jacobs I.J., Skates S.J., MacDonald N., Menon U., Rosenthal A.N., Davies A.P., Woolas R. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet. 1999; 353 (916): 1207-10.
  54. Depriest P.D., Varner E., Powell J., Fried A., Puls L., Higgins R. The efficacy of a sonographic morphology index in identifying ovarian cancer: a multi-institutional investigation. Gynecol. Oncol. 1994; 55: 174-8.
  55. Sato S., Yokoyama Y., Sakamoto T., Futagami M., Saito Y. Usefulness of mass screening for ovarian carcinoma using transvaginal ultrasonography. Cancer. 2000; 89 (3): 582-8.
  56. American Cancer Society. Detailed guide: ovarian cancer - can ovarian cancer be found early? (Accessed June 12, 2009, at http://www.cancer.org/docroot).
  57. ACOG Committee on Gynecologic Practice. The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer. Gynecol. Oncol. 2002; 87: 237-9.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.